You seem to have missed that ECA control arms require PRE-TRIAL design and mutual agreement. NWBO initiated their ECA control virtually POST-TRIAL, announced two weeks before data lock. It's why they aren't having FDA review, because it violated FDA's guidelines. Let's see if MHRA violates their new guidance with the DCVax-L review.
Market Data 
Markets 
AI
